Antiparasitic Drug Class List

Drugs in Drug Class: Antiparasitic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	STROMECTOL	ivermectin	TABLET;ORAL	050742-002	Oct 8, 1998	AB	RX	Yes	Yes
Merck Sharp Dohme	STROMECTOL	ivermectin	TABLET;ORAL	050742-001	Nov 22, 1996		DISCN	Yes	No
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes

Market Dynamics and Patent Landscape for Antiparasitic Drugs

Last updated: April 25, 2026

What do antiparasitic markets look like by indication?

The antiparasitic category is broad, spanning protozoal diseases (e.g., malaria, leishmaniasis, trypanosomiasis, toxoplasmosis) and helminthic diseases (e.g., soil-transmitted helminths, schistosomiasis, onchocerciasis, lymphatic filariasis). Market shape is dominated by two forces: (1) endemic-country procurement and public-health programs and (2) cycle time of major “mass drug administration” (MDA) products whose pricing is often constrained by tender regimes.

Core demand drivers

• MDA and disease-control programs: Continuous demand volumes with price pressure and multi-year procurement cycles.
• Geographic concentration: Sales skew to endemic regions; commercial returns depend on donor/NGO tenders and ministry procurement rather than only private pay.
• Regimen reuse: Many indications rely on established combinations; incremental uptake depends on resistance, safety, and adherence advantages rather than purely new targets.

Patent-protected value pools (high-level)

Across antiparasitics, protected value clusters around:

• New chemical entities (NCEs) in protozoal disease with high unmet need (malaria, late-stage leishmaniasis, trypanosomiasis).
• Next-generation formulations (e.g., single-dose regimens, co-formulations, pediatric dosing) that can extend commercial life even when APIs are older.
• Line-extension around resistance management where prior drugs lose efficacy.

How do manufacturing, regulation, and resistance shape market timing?

Manufacturing and supply constraints

• Many antiparasitic actives are small-molecule oral drugs with mature synthetic routes, enabling rapid generic entry once patent terms expire.
• Counterbalance comes from API consistency requirements for endemic procurement and controlled-substance-like operational rigor in some programs (traceability, lot release, pharmacovigilance).

Regulatory posture

• Endemic-region approvals often follow expedited timelines tied to public-health needs, but post-marketing commitments can be demanding.
• Combination approvals and pediatric label expansions can drive incremental demand even after initial approval.

Resistance dynamics

Resistance is the key factor that can re-open market growth:

• Malaria: Drug resistance drives switching and combination use; new mechanisms can capture share if they align with treatment guidelines.
• Helminths and onchocerciasis/filariasis: Resistance is less uniformly documented than malaria but treatment failures can still shift demand toward products with better durability, safety, or dosing convenience.

What does the patent landscape look like across the antiparasitic universe?

Antiparasitic patent portfolios typically follow a predictable structure:

1. Compound patents (core compositions of matter).
2. Salt/polymorph and hydrate patents (crystal form protection).
3. Formulation patents (fixed-dose combinations, extended release, improved solubility, dispersible tablets).
4. Use patents (new indication, dosing regimen, combination therapy).
5. Manufacturing process patents (less common for major commercial entries but present).

Patent longevity patterns

• For older antiparasitics, compound patents and some formulation patents have mostly expired in major jurisdictions.
• Value for “legacy” drugs increasingly comes from:
  • brand-to-generic lifecycle management
  • evergreening around combinations and pediatric regimens
  • regulatory exclusivity and data protection in some markets
  • commercial contract wins rather than fresh patent headroom

Where are the biggest patent “gates” in major antiparasitic segments?

Below is a segment-by-segment view of where the patent landscape most often determines market access.

Malaria (high intensity IP activity)

Malaria is where new mechanisms and combination strategies repeatedly reset patent leverage:

• IP tends to concentrate around new active ingredients, combination regimens, and pediatric/safety dosing.
• Guideline inclusion and procurement adoption drive commercial survival through patent life.

Leishmaniasis and trypanosomiasis (smaller base, high IP relevance)

These diseases have fewer commercial entrants, so portfolios can remain IP-relevant longer in relative terms:

• Drug repurposing + new dosing can still trigger use patents if the dosing regimen is novel and supported.
• The commercial market is driven by specialist procurement, donor funding, and WHO-related pathways.

Helminths (often older APIs with heavy generic presence)

Helminths frequently show a mature IP and generic landscape:

• Large-scale demand is stable, so procurement favors supply reliability and cost.
• Competitive space often hinges on whether a product has still-active formulation or combination patents, and on regulatory exclusivity (where applicable).

How does generic entry typically unfold?

Patent cliffs in antiparasitics are usually followed by:

• generic API entry (bioequivalence or bridging studies depending on jurisdiction)
• brand switching by tenders
• price compression and margin reduction across distributors and manufacturers

The practical outcome is:

• If a firm holds only compound patents and no meaningful formulation/use protection remains, it typically faces early share loss.
• Portfolios with multiple patent families tied to formulation or regimen can delay commoditization.

---

Patent landscape: what matters for investors and R&D planners?

For antiparasitics, business-critical diligence centers on freedom-to-operate (FTO) and exclusivity stacking.

What to map in every candidate portfolio

• Primary compound families: filing date, priority, claim scope, and expected expiry in key jurisdictions (US, EP, CN, IN).
• Secondary families: salts, polymorphs, solvates, and fixed-dose combinations.
• Regimen and use claims: dosing frequency, pediatric regimens, combination schedules.
• Competitor holdings: not only the innovator but also firms likely to challenge via generic or authorized generics.

How claim scope translates to market risk

• Broad genus claims reduce generic entry risk but can face validity challenges.
• Narrow formulation/use patents often still matter because generic entrants must redesign dosage forms or combinations to avoid infringement.

---

Which patent sources and legal instruments dominate antiparasitic freedom-to-operate?

US

• Orange Book listings (where available) identify approved drugs, applicants, and patents tied to those products.
• Patent term and extension can materially extend the life of eligible patents, especially when prosecution timelines compress.
• Hatch-Waxman paragraph IV challenges are a key litigation pathway around patent cliffs.

Europe

• EPO granted patents and national validations drive enforcement.
• Supplementary Protection Certificates (SPC) can extend patent protection for medicinal products meeting eligibility criteria.

China and other high-volume markets

• Practical infringement and enforcement depend on local filings, local validations, and marketing authorization linkages.

---

Operational model: how market dynamics and patent cliffs intersect

The antiparasitic category usually prices around:

• tender outcomes (public-sector and donor contracting)
• measurable regimen performance (adherence, dosing convenience, pediatric safety)
• programmatic procurement lead times

As a result, timing is not only legal. It is execution:

• The effective market loss may occur before the strict expiry date when procurements are pre-planned and vendor onboarding takes time.
• Conversely, successful lifecycle management via formulation/regimen IP can extend market position even after compound expiry.

---

Market dynamics by drug class subfamily (practical investment lens)

The following framework helps investors judge where patent-protected value is most durable.

1) Novel mechanism antiparasitics

• Higher chance of multi-family IP across molecule + regimen + combination.
• Higher clinical adoption impact, but also higher probability of guideline dependence.

2) Reformulated or co-formulated regimens

• IP risk is lower when multiple patents cover dosing forms and fixed-dose combinations.
• Returns are often tied to procurement acceptance and pediatric/program labeling.

3) Legacy APIs with expired compound patents

• Value depends on:
  • supply reliability
  • low-cost manufacturing
  • remaining use/formulation protection (if any)
  • tender contracts and distribution networks

---

Key Takeaways

• Antiparasitic market dynamics are driven more by endemic procurement cycles and program adoption than by typical commercial demand elasticity.
• The patent landscape is typically layered: compound + salts/polymorphs + formulation/combination + dosing/use. Investors should treat compound expiry as only one piece of the risk.
• Malaria and other protozoal diseases show the most active IP reset cycles due to resistance and guideline updates.
• Helminth markets are often more commoditized, so residual value depends on whether formulation and regimen patents remain enforceable.
• Patent cliffs can translate into earlier market share loss because procurement lead times and tender pre-selection start well before formal expiration.

FAQs

1) What patent types most delay generic entry in antiparasitics?
Fixed-dose combinations, salts/polymorphs, and dosing regimen/use patents often delay entry when they force generics to redesign the product or regimen.

2) Why do tenders matter as much as patent life in this category?
Public-health programs lock procurement schedules in advance, so incumbents can lose share early if replacements are qualified before formal expiry.

3) Is resistance the main market driver only for malaria?
Resistance most clearly reshapes malaria economics, but treatment failures and durability concerns also affect helminths and protozoal diseases, changing regimen adoption.

4) How should portfolios be evaluated for FTO?
Map all active patent families tied to the marketed product and its key regimens, including formulation and combination patents, and check key jurisdictions where procurement will occur.

5) What is the typical post-expiry market outcome?
A rapid shift toward lower-cost generics is common, with incumbents retaining value only where secondary IP and regulatory/data protections remain.

---

References

[1] World Health Organization. Guidelines for the treatment of malaria (latest consolidated guidance as published by WHO). WHO. https://www.who.int/teams/global-malaria-programme
[2] European Patent Office (EPO). Supplementary Protection Certificate (SPC) information and framework. EPO. https://www.epo.org
[3] U.S. FDA. Drugs@FDA and Orange Book patent listing framework. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[4] U.S. FDA. Hatch-Waxman Amendments: Overview of Abbreviated New Drug Applications (ANDAs) and patent certifications. FDA. https://www.fda.gov/